GEN Exclusives

More »

GEN News Highlights

More »
Dec 18, 2008

Adolor Shutters Phase III Development of OBD Drug

  • Adolor is nixing development of Entereg, its Phase III candidate for chronic opiate bowel dysfunction (OBD). In September, GlaxoSmithKline returned rights to Entereg covering various bowel dysfunction indications but retained rights to development in postoperative ileus (POI).

    Adolor reports that it based its decision on an assessment of the cost and timeline for an additional Phase III study relative to the remaining commercial life of Entereg in OBD.

    Instead, Adolor will focus on preclinical ADL7445, a peripherally acting mu-opioid receptor antagonist. The firm says that it is on track for for submission of an IND in mid-2009.

    Entereg received FDA approval earlier this year for the management of POI following bowel resection surgery.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »